Augmentation of natural chimerism with donor bone marrow in orthotopic liver recipients by Rao, AS et al.
t j 
Augmentation of Natural Chimerism With Donor Bone Marrow 
in Orthotopic Liver Recipients 
A.S. Rao, P. Fontes, F. Dodson, A Zeevi, M.T. Rugeles, K. Abu-Elmagd, A Aitouche, G. Rosner, 
M. Trucco, AJ. Demetris, W. Rybka, S. Todo, J.J. Fung, and T.E. Starzl 
WITH the concept that the persistence of donor leu-kocyte chimerism plays a seminal role in the accep-
tance of whole organ allografts,I-4 we initiated a prospec-
tive trial in December 1992 to enhance chimerism by 
adjuvant infusion of unmodified donor bone marrow (BM) 
in liver, kidney, and thoracic organ recipients.5 Conven-
tional tacrolimus/prednisone immunosuppression was given 
without any kind of recipient preconditioning. We report 
the outcome of the first 34 liver transplantations, along with 
29 contemporaneous control cases in which permission 
could not be obtained for BM removal from the cadaveric 
liver donors. 
MATERIALS AND METHODS 
Patients 
The 34 transplantations were between March 1993 and December 
1994, all from ABO compatible donors. Typing was random and 
the matching was poor, and in 24% of the cases, the cytotoxic cross 
match was positive after dithiothreitol treatment (Table 1). A 
diabetic patient reported elsewheres also received pancreatic islets. 
The infused BM was not T-cell depleted or modified in any other 
way, and the recipient was not pre-treated or preconditioned with 
cytoablative or cytoreductive procedures. Twenty-nine recipients of 
liver allografts served as controls because permission to remove 
BM from the cadaveric liver donors could not be obtained. The 
majority of study (74%) and control (83%) patients were at United 
Network for Organ Sharing (UNOS) 1lI or IV urgency status at the 
time of operation. Demographic data arc given in Table 1. 
Table 1. Demographic Profile of Bone Marrow-Augmented and 
Nonaugmented Orthotopic Liver Transplant Recipients 
Bone Marrow Bone Marrow 
Augmented Nonaugmented 
Demographic (n = 34) (n = 29) 
Age (yr; x = SO) 
Recipients 53 = 9 52 = 12 
Donors 35 = 16 44 = 19 
Sex (recipient) 
Males 15 14 
Females 19 15 
Cross-Sex Transplants 
Male - Female 12 10 
Female - Male 5 5 
Follow-up (d) 
Range 165 to 787 231 to 565 
Mean = SO 398 = 157 458 = 90 
HLA 
Matches (X = SO) 1.2 = 1.2 1.7 = 1.2 
Mismatches (X = SO) 4.8 = 1.2 4.3 = 1.2 
Lymphocytotoxic Crossmatch 
Positive 8(24%) 6(21%) 
BM Processing 
BM cells were isolated from thoracolumbar vertebrae with minor 
modifications from the previously described methods.s The sepa-
rated vertebrae were crunched in addition to the original chipping 
procedure. The media and process were otherwise the same. In a 
second alteration, the cells were suspended in lactated Ringer's 
solution containing 2.5% human serum albumin, 0.5 mg/mL gen-
tamicin, and 10 U/mL heparin (rather than a special "suspension 
solution") before infusion into the recipients via a central intrave-
nous (IV) line. In a third alteration from the original protocol, the 
isolated BM cells were filtered (mesh size 180 J.l.) three times before 
and after refrigeration and immediately before infusion. This 
modification was made to avoid the accidental infusion of micro-
scopic bone chips that had been detected in the solution. The dose 
was 3 to 5 X lOB cells/kg body weight, resuspended in approxi-
mately 200 mL of the lactated Ringer's solution. A sample of the 
final infusate was withheld for progenitor cell assays and for 
microbial testing. 
Immunosuppression 
Tacrolimus (FK 506, Prograf, Fujisawa Pharmaceutical Co, Osaka, 
Japan) and prednisone were begun intraoperatively. The daily 
doses of tacrolimus (beginning at 0.05 IV and 0.20 orally) were 
targeted to achieve whole blood levels of 10 to 20 ng/mL in the first 
1 or 2 weeks and 6 to 12 ng/mL thereafter. However, dose 
adjustments up or down were individualized from the first day 
onward. based on side effects and/or allograft function. One 
Iiver/BM-recipient with marked pre-transplant encephalopathy did 
not recover normal neurological function by 17 days (disorientation 
and delayed responses) and was permanently switched to oral 
cyclosporine (400 mg/d, Sandoz Pharmaceuticals. East Hanover. 
NJ). Although dramatic improvement did not occur. he has steadily 
recovered over a period of 6 months and is out of the hospital. 
Prednisone was begun with a one gram bolus intraoperatively, 
followed with a 5-day cycle (200 -- 20 mg). Episodes of acute 
rejection were treated with a methylprednisolone bolus (1 gm, IV) 
and a 5-day steroid recycle if necessary. A course of OKTI (5 mg/d, 
IV for 7 to 14 days) was given for steroid-resistant rejection, and 
azathioprine was added if indicated. to control rejection or mini-
mize tacrolimus toxicity. Drug doses were progressively reduced in 
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Table 2. Criteria Used to Serially Evaluate In Vitro Mixed 
Leukocyte Responses of Transplant Recipients 
Proliferative Responses 
Categories Donor-Specific· DonorfThird Party 
Suppressedt Markedly reduced Markedly reduced 
Hyporeactive Decreased Decreased 
« 20%) (60% to 70%) 
Intermediate Decreased Decreased 
(50% to 60%) (40% to 50%) 
Reactive No change No change 
·Post- versus pre-transplant responses. 
tNonspecifically diminished response to mitogens as well as alloantigens. 
all patients with the usual trial and error establishment of mainte-
nance therapy. 
STUDIES OF CHIMERISM 
The presence of donor cells in the recipient's peripheral 
blood mononuclear cells (PBMC) was evaluated weekly in 
the first month posttransplantation and every other month 
thereafter. 
Flow Cytometry 
As reported previously, single and double-color immuno-
fluorescence techniques were used to distinguish donor 
from recipient cells.s After staining, the samples were 
analyzed using an EPICS Elite Flow Cytometer (Coulter 
Corp, Hialeah, FL). Unstained and cells stained with 
appropriate fluorochrome-conjugated isotype-matched ir-
relevant monoclonal antibodies (MAbs) were used as neg-
ative controls. Fifty-thousand (lymphocytes) events were 
acquired for analysis with open, as well as with gates 
encompassing the lymphocyte or monocyte populations. In 
selected cases, recipient PBMCs, stained with various lin-
eage-specific MAbs (CD3, CD22, CD56) were sorted, and 
the presence of donor DNA was detected subsequently by 
polymerase chain reaction (PCR) analysis (see below). 
PCR 
Donor DNA was detected in the recipient's peripheral 
blood or sorted cells by a procedure described previous-
lyKzK4K~ This technique allowed for detection of as low as one 
donor/l05 to lOll recipient cells. 
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IMMUNOLOGICAL RESPONSIVENESS 
Pretransplant and serially posttransplant (every other 
month) monitoring of recipient's immune status was per-
formed by evaluating the proliferative responses of their 
PBMCs to mitogens (concanavalin A, phytohemagglutinin 
antigen), recall antigens (tetanus toxoid), mixed leukocyte 
reactions, and limiting dilution assays. These assays as well 
as detailed studies of many of these same patients have 
been described elsewhere.6 The criteria used to serially 
evaluate in vitro immune responses is detailed in Table 2. 
STATISTICAL ANALYSIS 
Comparative analysis of the risk of rejection was performed 
using the log-rank (Mantel-Cox) test. The cumulative risk 
of rejection was computed using the Kaplan-Meier (prod-
uct-limit) method. Risk estimates were determined using 
the following formula: 1 - Set), where Set) is the cumulative 
probability of being rejection-free at time (t). Patients 
who were lost during the follow-up (ie, died free of rejec-
tion) were censored from the final analysis. Continuous 
variables were compared using the two sample t-tests under-
taken by using Fisher Exact Test and chi-square test. A 
P value less than 0.05 was considered statistically significant. 
RESULTS 
Clinical Course 
No complications of BM infusion were observed in any of 
the 34 primary liver allograft recipients and their recuper-
ation was rapid. Their follow-up ranged from 165 to 787 
days (Table 1). Two liver recipients died on postoperative 
days 23 and 35 of infections and multiple organ failure. The 
surviving 32 (94%) patients are well with a mean serum 
bilirubin level of 0.6 :!: 0.2 mg/dL (maximum, 1.2 mg/dL) 
(Table 3). In addition to tacrolimus (9.1 :!: 5.6 mg/d), 3 
(9%) are also receiving Imuran (42 :!: 14 mg/day). Pred-
nisone has been discontinued in to of 32 (31%) of the 
patients (Table 3). 
Of the 29 patients who received liver allografts alone, 4 
(14%) have died of various causes within the first year after 
transplantation. The remaining 25 have optimally function-
ing allografts (mean bilirubin = 0.7 :!: 0.3 mg/dL; maximum, 
1.6 mg/dL). These recipients are currently being maintained 
on variable doses of tacrolimus (7.7 :!: 3.4 mg/d), pred-
nisone (3.2 :!: 3.7 mg/d), and in 5 cases azathioprine (55 :!: 
27 mg/d). Prednisone has bcen discontinued in 13 of 25 
Table 3. Current Graft Function and Immunosuppression Profile of Bone Marrow Augmented and Nonaugmented Liver 
Transplant ReCipients 
Graft Survival' Bilirubin Tacrollmus SterOids Patients Off-SterOids (mgldL) (mgld) (mgld) 
OLT n n (%) (X:: SO) (X:: SO) (X:: SOl n (%) 
8M-augmented 34 32/34 (94%) 0.6 :! 0.2 9.1 :! 5.6 5 :! 4.8 10/32 (31%) 
Nonaugmented 29 25/29 (86%) 0.7 :! 0.3 7.7 :! 3.4 3.2 :! 3.7 13/25 (52%) 
'Actuarlal 1-year. 
AbbreViations: OLT. orthotopIC liver transplantation: 8M. bone marrow. 
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Fig 1. The cumulative risk of 
rejection in bone marrow-eug-
mented and nonaugmented 
liver allograft recipients as com-
puted by the Kaplan-Meier 
(Product-Limit) method. There 
was no statistically significant 
difference in the risk between 
the two groups (P = .65). 
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(52%) patients, 2 of whom also receive azathioprine 
(Table 3). 
Rejection and Graft-Versus-Host Reaction 
Biopsy verified liver rejection followed the same tempo in 
the BM-augmented and nonaugmented recipients. occur-
ring in 16 of 32 (50%) of study and 13 of 25 (52%) of 
control patients. The cumulative risk (Fig 1), as well as the 
histopathological severity of rejection. were similar in both 
groups, and responded to adjustments of conventional 
immunosuppression. In 2 of 32 (6%) study and 2 of 25 (8%) 
control patients. OKT3 was required to treat steroid-
resistant rejection. 
Histopathologically proven asymptomatic graft-versus-
host disease (GVHD). limited to the skin. was observed in 
2 of 32 (6%) 8M-augmented patients. On postoperative 
day 54. one patient developed a papulomacular rash (grade 
II) involving the trunk, which responded to a transient 
increase in her steroids (7.5 - 15 mg/d). The other patient 
had two episodes of macular rash (grade < I) on postop-
erative days 21 and 74. respectively; both resolved sponta-
neously within 1 to 2 weeks. 
Donor Cell Chimerism 
Using either PCR (Fig 2) and/or flow cytometry (Fig 3). 
30/31 (97l1-) evaluable 8M augmented and 13 of 25 (52%) 
control patients had evidence of circulating donor cells in 
their peripheral hlood at the last sample tested (Table 4). 
The unavailability of MAb andlor primers for donor-
specific H LA class I or II alleles precluded these studies in 
one same-sex 8M-augmented recipient. The chimerism was 
of multilineage character (Figs 3 and 4). and the presence 
of donor T. B. and natural killer cells was confirmed in the 
recipient PBMCs by PCR studies of a blood sample ob-
tained at 59(} days post-transplantation (Fig 4). 
In Vitro Immune Monitoring 
Because of the lack of recipients' pre-transplant blood 
andlor donor splenocytes. serial immune monitoring was 
not possible in 7 of 32 (22%) of the BM-augmented and 2 
of 25 (8%) of the control patients. At the last sample tested, 
a higher (13 of 25; 52%; P < .05) proportion of study 
patients exhibited stable donor-specific hypo reactivity as 
compared with that of the controls (6 of 23; 26%; Table 5). 
Vigorous donor-specific immune reactivity was observed in 
14 of 23 (60%) of recipients in the control group as 
compared to 11 of 25 (44%) of those in the study (Table 5). 
These differences barely achieved statistical significance. 
DISCUSSION 
The germination of this trial was the realization that the 
bone marrow-derived multilineage leukocyte component of 
whole organs (commonly known as passenger leukocytes) 
begins to migrate ubiquitously within a few minutes after 
transplantation and that these donor cells survive. They 
constitute a small second cell population that is capable of 
defending itself against the immunologic system of the 
recipient. 1-4.7-9 We have postulated in what has been called 
the two-way paradigm.1O that the eventual induction of 
mutual nonreactivity of the co-existing cell populations. 
each to the other. is the essential basis of allograft accep-
tance no matter what the organ!-.u-12. 
The ramifications of the two-way paradigm are too vast to 
consider in this brief report. In this article we have ad-
dressed onlv the narrow issue of augmenting the chimerism 
emanating' from the organ by th~e simple expedient of 
adding donor 8M. The foremost clinically relevant ques-
tions are of safety and efficacy. Concerns ahout safety have 
been largely laid to rest. not only by the experience reported 
here with livers. but also in similar trials in kidney'J and 
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Fig 2. Serial detection of do-
nor DNA in the peripheral blood 
mononuclear cell of a liver bone 
marrow recipient for up to 590 
days posttransplantatlon. I: TI-
tration curve of donor-specific 
HLA class II (DR14l: a log dilu-
tion from 100 to 0.001 ng In 
lanes A to E respectively. II: Do-
nor DNA was detectable on 
POD 252 (lane Al, 280 Oane B), 
294 (lane C) and 590 Oane D). 
Lanes IF and liE are negative 
controls. 
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thoracic organ recipients. 14 The clinically insignificant skin 
rashes in two liver recipients have been the only examples of 
the once-feared complication of GVHD in the entire 
Pittsburgh experience. 
Although the efficacy question cannot be answered deci-
sively, the extraordinarily high patient and graft survival in 
this series of high-risk liver transplant recipients is notewor-
thy. In contrast, our past experience with such cases was 
faithfully reproduced with the higher mortality of the 
non-BM control recipients. Not a single patient among the 
32 who now have been followed for from 6 months to more 
than 2 years has the slightest evidence of hepatic graft 
dysfunction. Similar results in the surviving control recipi-
ents bespeak the exceptional efficacy of tacrolimus-based 
immunosuppression. The chimerism in the BM-augmented 
patients could usually be detected with flow cytometry as 
would be predicted from the experimental studies of Mu-
rase et al.9 In Murase's experiments, there was a nearly 
perfect correlation between the extent of chimerism in rats 
and freedom from rejection of liver, heart, and other kinds 
of allografts. The liver produced the greatest chimerism of 
any organ. 
It also was shown by Murase et al9 that not all donor 
leukocytes sources are therapeutically equal. When equal 
numbers of cells were prepared from the thymus and 
secondary lymphoid organs, only those from BM, with its 
high proportion of leukocytes of undetermined lineage 
(presumably including precursor and stem cells), were 
highly tolerogenic while not causing GVHD. The liver was 
the most tolerogenic whole organ with little tendency to 
cause GVHD in the GVHD-prone rat model used in these 
experiments. In contrast, the lymphoid-rich intestine invari-
ably caused GVHD.'1 
Much more needs to be learned about the reason for 
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these disparities in the effect of leukocytes from different 
locations. However, circumstantial evidence suggests that a 
high proportion of dendritic cells, macrophages, and per-
haps other cells of myeloid lineage are critical for the 
desired result of safe graft acceptance. The prominence of 
chimeric donor dendritic cells in human whole organ recip-
ients as long as 30 years posttransplantationl-4.1 2 has 
directed much attention to this antigen-presenting cell as 
the key factor in the orchestration of allograft tolerance. 
Presumably, the outcome in a given circumstance (sensiti-
zation versus tolerance) is dependent on the way dendritic 
cells present alloantigen to the T lymphocyte. Increasing 
attention has been directed by Steinman, rnaba, and Aus-
tyn IS and by Thomson and Lu et a1 16- 18 towards the 
potentially dualistic capabilities of the dendritic cell. 
Whatever the mechanisms are proven to be, it should be 
emphasized that chimerism, although essential for organ 
allograft acceptance and the induction of donor-specific 
nonreactivity, is not synonymous with either. In a clinical 
context, we originally stated that "clinical success-[wheth-
er called] tolerance or graft acceptance-means that a 
characteristic lymphoid and dendritic cell chimerism has 
been introduced which may be stable either without further 
treatment, or only when continued immunosuppression is 
provided; an unstable graft and its migrated cells may either 
be rejected or cause GVHD."I 
At a practical level, this statement of principle is hardly 
an invitation to believe that measuring the level of chimer-
ism will predict when drugs can be stopped or that these 
levels should be used to guide drug dosing. Although 
complete drug discontinuance has been frequently achieved 
long after the transplantation of non-8M-augmented liver 
recipients;' Ramos et al''1 have provided a road map with 
warning signs for those who would aspire to premature 
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Fig 3. Detection of HLA-A2+ donor cells by flow cytometry in a liver and bone marrow recipient using wide analysis gate (IA). One 
pOint seven percent of circulating donor cells (IE) were identified in the recipients' peripheral blood mononuclear cells obtained on 
postoperative day 380. Furthermore, analysis of cells within the lymphocyte (IIA) or monocyte (IliA) gates also revealed the presence 
of 1.1 % (liE) and 2.5% (IIIE) of donor cells, respectively, confirming the multilineal nature of donor-cell chimerism. All analyses were 
performed on an EPICS Elite Flow Cytometer (Coulter Corp, Hialeah, FL). 
weaning.;!) In our drug weaning trials. no liver recipient has 
been considered for the final step of elective drug stoppage 
unless they were free of immunologic complications for at 
least 5 to 10 years. 
The observations reported herein hold promise of ex-
panding our grasp of human immunology, while at the same 
time improving patient care. For example. while Monaco 
and Wood have long contended that organ allograft accep-
tance could be facilitated by giving donor BM.ll it was 
generally thought that these cells were short-lived. Human 
trials of 8M-augmentation for renal transplantation by 
Monaco;~ and Barber.2J as well as for liver transplantation 
by Rollesl4 have provided equivocal or disappointing re-
sults: our results so far should be viewed as equivocal. Until 
recently. fate of the injected cells was unknown but assumed 
to be of limited duration. For this reason. it was logical to 
judge therapeutic efficacy on the basis of early posttrans-
plantation events such as the incidence and severity of acute 
rejection or short-term patient and graft survival. The 
experimental studies of Murase et aI" and Shin et al25 have 
made it clear the tolerogenic effect of histoincompatible 
donor leukocytes. originating either from the graft. or given 
separately as with BM-augmentation. has the long-term 
objective of preventing chronic rejection. It seems obvious 
Table 4. In Vitro MLR Responses in Bone Marrow-Augmented and Control Patients· 
Evaluable 
OLT n (%) Hypo/Intermediate (%) 
BM augmented 
Controls 
. At the last sample tested. 
25/32 
23/25 
(78%) 
(92%) 
I See Table 2 for details regarding the criteria used to categorize responses. 
I Bone marrow-auqmented versus contrOls; p. as. 
13/25 (52%)1 
06/23 (26%) 
MLR Responses (n. %)f 
Reactive 1%) 
11/25 (44%) 
14/23 (61 %) 
AbbreViations: MLA. mixed lymphocyte reaction; OL T. onhotoplc liver transplantation: BM. bone marrow. 
Suppressed (%) 
01/25 (04%) 
03/23 (13%) 
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Fig 4. Analysis for the lineage of donor-cells in the peripheral blood mononuclear cell of a bone marrow-augmented liver recipient 
590 days posttransplantation. Using lineage-specific monoclonal antibodies, T(C), NK(D) and B(E) cells were sorted, and the presence 
of donor DNA (inset) within the sorted populations were confirmed by polymerase chain reaction. (B) Autofluorescence of unstained 
cells. (C) Negative control. Titration curve for DR14 (donor-specific HLA) at log dilution from 100 ng (lane 1) to 0.001 ng ~ane 5). PGE: 
percentage gated events. 
that the donor-specific blood transfusion effect, first re-
ported by Salvatierra et al.26 is a variation of the same 
principle of chimerism as was postulated by van Twuyver et 
a\.27 
In conclusion. in an attempt to augment the spontaneous 
donor cell chimerism which we have postulated to be the 
explanation of allograft acceptance, we infused 3 to 5 X 108 
unmodified donor BM cells/kg body weight into 34 adult 
primary liver allograft recipients (53 :t 9 years old) for 
whom mean follow-up is 398 days (range. 165 to 787 days). 
Mean donor age was 35 :t 16 years. Routine immunosup-
pression was with tacrolimus and prednisone. There were 
no complications of BM infusion. Two patients (one with a 
positive cytotoxic cross match, 1: 1,024) died of infections 
and multiple organ failure after 23. and 36 days. respec-
tively. All 32 (94%) surviving patients are well with a mean 
serum bilirubin level of 0.6 :t 0.2 mg/dL (maximum, 1.2 
mg/dL). Sixteen (50%) of the 32 long-surviving patients had 
mild to moderate rejection which was responsive to con-
ventional secondary adjustments of immunosuppression 
(two requiring OKT3). Two patients with asymptomatic 
skin rash were shown by biopsy to have histopathologic 
findings of grade \-2 GVHD disease which involuted 
spontaneously in one, and after a transient increase in 
prednisone (7.5 ~ 15 mg/d) in the other. Prednisone has 
heen discontinued in 10 of 32 (31 %) of the patients. Donor 
hlood cell chimerism was detected in 3D of 31 (l)7%) 
evaluahle patients with flow cytometry and/or peR. In II 
ERT~F of 25 evaluable recipients. stable donor-specific 
hyporeactivity was shown with in vitro testing. Twenty-nine 
recipients for whom BM was not available hecause of 
failure to obtain donor family consent made up a contem-
poraneous control group. Four (14%) died of various 
causes during the 231- to 565-day follow-up period. Low-
level chimerism was shown in 13 (52%) at last sampling. Six 
(26%) of 23 evaluable patients exhibited donor-specific 
hyporeactivity by the time of the last blood sampling. This 
experience indicates that adjuvant infusion of BM for liver 
allograft recipients is safe and augmented the level of 
chimerism. There was a trend towards more frequent 
development of stable donor-specific nonreactivity in the 
BM-augmented patients than in the controls. 
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